Roche's Tecentriq Based Combination Therapy Receives EC's Approval as 1L Treatment for Non-Squamous Non-Small Cell Lung Cancer
Shots:
- The approval is based on P-III IMpower130 study assessing Tecentriq + CT (carboplatin and nab-paclitaxel) vs CT alone in 723 CT naive patients in ratio (2:1) with stage IV non sq. NSCLC who do not have EGFR mutant or ALK-positive NSCLC
- The P-III IMpower130 study results: median OS (18.6 vs 13.9 mos.); mPFS (7.0 vs 5.5 mos.); ORR (49.2% vs 31.9%); mDoR (8.4 vs 6.1mos.); AEs (73.2% vs 60.3%)
- Tecentriq is a mAb targeting PD-L1 act by blocking its interaction with PD-1 and B7.1 receptors thus leading to the activation of T cells and is an approved therapy in multiple countries across the globe including the US and EU as a monothx. or combination therapy for NSCLC and SCLC
Click here to read full press release/ article
Ref: Roche | Image: Roche
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com